Before Thursday’s opening bell, a number of big name dividend stocks were the subject of analyst moves. Below, we highlight the important analyst commentary for investors.
Stifel Downgrades American Eagle
American Eagle Outfitters (AEO) was downgraded from “Buy” to “Hold” at Stifel Nicolaus. The ratings company does not believe that the company’s turnaround is as visible as management has claimed. AEO has a dividend yield of 3.49%.
Dick’s Gets Downgrade
Morgan Stanley downgraded Dick’s Sporting Goods (DKS) to “Equal-Weight” due to a survey that suggests DKS could have increased competition in the near future. DKS has a dividend yield of 0.93%.
Hot Industrial Conglomerate Companies For 2016: ImmunoGen Inc.(IMGN)
ImmunoGen, Inc. engages in the research and development of targeted therapeutics for the treatment of cancer using cancer biology, monoclonal antibodies, and highly potent cell-killing agents. The company develops its products using its Targeted Antibody Payload (TAP) technology. Its product candidates include Trastuzumab emtansine (T-DM1), a Phase III clinical trial product for HER2+ breast cancer; lorvotuzumab mertansine (IMGN901), a Phase I clinical trial product, which targets CD56 found on small-cell lung cancer, Merkel cell carcinoma, multiple myeloma, ovarian cancers, carcinoid tumors, and other cancers of neuroendocrine origin; IMGN529, a pre-investigational new drug stage drug for CD37+ B-cell malignancies, such as non-Hodgkin's lymphoma; and IMGN853, a preclinical stage product for cancers that overexpress folate receptor 1, including ovarian cancer. The company?s earlier-stage compounds in development stage comprise SAR3419, a Phase I clinical trial product for CD19+ B-cell malignancies, including non-Hodgkin's lymphoma; SAR650984, a Phase I clinical trial product for CD38+ hematological malignancies; SAR566658, a phase one clinical trial product for DS6+ solid tumors; and BT-062, a Phase I product for multiple myeloma. It has collaboration agreements with Amgen, Inc.; Bayer Schering Pharma AG; Biogen Idec MA Inc.; Biotest AG; Genentech, Inc.; Novartis Institutes for BioMedical Research, Inc.; and sanofi-aventis U.S. LLC. ImmunoGen, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.
Advisors' Opinion:- [By Sean Williams]
High-risk, high-reward suggestions
Exelixis (NASDAQ: EXEL ) : In November Exelixis had its first drug, known as Cometriq, approved by the Food and Drug Administration to treat metastatic medullary thyroid cancer. Although the market for this disease is pretty small -- somewhere between 500 and 700 people in the U.S. -- the near-tripling in progression-free survival, or PFS, in trials would indicate to me a strong likelihood that it could translate to success in other cancer types. In mid-stage prostate cancer trials, for instance, Cometriq was found to be particularly effective in dealing with bone metastases as a second or third-line treatment. We won't get any additional data until next year on Cometriq, but positive data on the prostate cancer front could be enough to double its share price if the PFS, compared to the placebo, is notably strong. ImmunoGen (NASDAQ: IMGN ) : In February, Roche�and ImmunoGen received approval for Kadcyla as a secondary treatment for HER2-positive breast cancer. This is ImmunoGen's first drug approval, and it gives the company a chance to showcase what I feel is one of the future pathways of fighting cancer -- its targeted-antibody payload, or TAP, technology. ImmunoGen's TAP technology works by attaching a toxin -- in this case Roche's Herceptin -- to an antibody, and teaching that antibody to release the to
There's an undeniably large dollar amount being pledged to cancer research, but, even if a drug gains approval, that's no guarantee that the biotech or pharmaceutical company behind that drug will be a success. Some of the biggest gains (and losses) come from taking a leap of faith based on clinical data, or the approval of one or two drugs or devices within a pipeline. After that, it's all up to the drug or devices' effectiveness, its pricing, and the success of the marketing teams promoting the drug or device. Here are a few high-risk, high-reward names you should be keeping your eye on.
Hot Heal Care Stocks To Invest In Right Now: OceanFirst Financial Corp.(OCFC)
OceanFirst Financial Corp. operates as the holding company for OceanFirst Bank that provides community banking services to retail, government, and business customers primarily in Ocean, Monmouth, and Middlesex counties in New Jersey. Its deposit products include money market accounts, savings accounts, interest-bearing checking accounts, non-interest bearing accounts, and time deposits. The company?s loan portfolio comprises conventional first mortgage loans secured by one-to-four family residences, residential mortgage loans, commercial real estate loans, multi-family and land loans, and real estate construction loans; consumer loans, such as home equity loans and lines of credit; and commercial loans. In addition, it offers trust and asset management, and merchant check card services; and sells alternative investment products, including mutual funds, annuities, and life insurance. The company operates 22 branches, as well as a loan production office and a trust and weal th management office. OceanFirst Financial Corp. was founded in 1902 and is based in Toms River, New Jersey.
Advisors' Opinion:- [By Garrett Cook]
In trading on Wednesday, financial shares were relative laggards, down on the day by about 0.24 percent. Top losers in the sector included IRSA Investments and Representations (NYSE: IRS), down 3.2 percent, and OceanFirst Financial (NASDAQ: OCFC), off 2.5 percent.
Hot Heal Care Stocks To Invest In Right Now: ALCO Stores Inc (ALCS)
Alco Stores, Inc., incorporated on June 2, 1915, is engaged in the business of retailing general merchandise throughout the central portion of the United States of America through a range of department store outlets. The Company�� ALCO stores offer a range of merchandise consisting of approximately 35,000 items, including automotive, commodities, crafts, domestics, electronics, furniture, hardware, health and beauty aids, housewares, jewelry, ladies�� men�� and children�� apparel and shoes, pre-recorded music and video, sporting goods, seasonal items, stationery and toys.
As of February 3, 2013, the Company operated 217 stores in 23 states located in mostly smaller communities in the central United States. The stores average approximately 21,000 square feet of selling space, with an additional 5,000 square feet utilized for merchandise processing, temporary storage and administration.
Advisors' Opinion:- [By Monica Gerson]
ALCO Stores (NASDAQ: ALCS) is projected to post its Q2 earnings.
Digital Cinema Destinations (NASDAQ: DCIN) is estimated to post a Q4 loss at $0.11 per share on revenue of $11.17 million.
Hot Heal Care Stocks To Invest In Right Now: Alcoa Inc.(AA)
Alcoa, Inc. engages in the production and management of primary aluminum, fabricated aluminum, and alumina. The company operates in four segments: Alumina, Primary Metals, Flat-Rolled Products, and Engineered Products and Solutions. The Alumina segment engages in mining of bauxite, which is then refined into alumina. The Primary Metals segment produces aluminum. The Flat-Rolled Products segment engages in the production and sale of aluminum plate, sheet, and foil. The Engineered Products and Solutions segment produces and sells titanium, aluminum, and super alloy investment castings, hard alloy extrusions, forgings and fasteners, aluminum wheels, integrated aluminum structural systems, and architectural extrusions. Its products are used in aircraft, automobiles, commercial transportation, packaging, building and construction, oil and gas, defense, consumer electronics, and industrial applications. The company holds interests in bauxite mining activities. The company has op erations primarily in the United States, Australia, Spain, Brazil, the Netherlands, Norway, France, the Russian Federation, Hungary, Italy, the United Kingdom, China, and Germany. Alcoa, Inc. was founded in 1888 and is based in New York, New York.
Advisors' Opinion:- [By Jeff Reeves]
Commodity stocks and materials stocks have been laggards for quite some time thanks to weak industrial demand and soft prices for base metals. But while Alcoa (AA) has bounced around between $8 and $10 since late 2011, there may be signs of a recovery ahead for this battered aluminum giant.
- [By Rich Smith]
Alcoa (NYSE: AA ) is expanding production capacity at its Kitts Green facility in the United Kingdom.
On Tuesday, the aluminum giant announced that it has completed a project that will help it soon quadruple the amount of third-generation aluminum lithium alloys it produces for the aerospace industry. According to the company, its revenues derived from the alloy are about $50 million annually today, but within six years' time could become a $200 million business.
- [By Ben Levisohn]
Alcoa (AA) has been making big changes–maybe not caterpillar to butterfly changes–but perhaps pollywog to frog. And that’s a good thing, says Deutsche Bank’s Jorge Beristain, who upgraded Alcoa’s shares today. He explains why its “metamorphosis [is] on track”:
BloombergWe admittedly are now “eating crow”, as we had misjudged the turn-around now apparent in Alcoa’s upstream Primary smelting business due to (still rising) US premia plus an improved global aluminum price. The net effect has been a resurrection of a business unit that had heretofore been a headwind for Alcoa’s overall finances…
Alcoa has focused shutting high-cost smelters/refineries, while simultaneously increasing exposure to more stable downstream segments (ie, aerospace, automotive and construction) over the past few years. These mix changes, along with higher-than-expected realized aluminum prices have led to a re-rating of the stock, which has risen 75% over the past 12 months. We believe these factors will continue to support an earnings turn-around and see upside driven mainly by Primary Metals EBITDA which could recover from a 2013 cyclical low of $475m to $1.8bn by 2016, despite a lower capacity footprint.
Shares of Alcoa have dropped 0.7% to $16.44 at 1:50 p.m.
No comments:
Post a Comment